Table 1.
FL n = 41 | LPL/WM n = 17 | MZL n = 17 | MCL n = 39 | Total N = 114 | |
---|---|---|---|---|---|
Male, n (%) | 20 (48·8) | 11 (64·7) | 11 (64·7) | 25 (64·1) | 67 (58·8) |
Median age, years (range) | 67 (41–89) | 72 (47–89) | 65 (52–83) | 72 (49–92) | 71 (41–92) |
Median prior therapies, n (range) | 3 (1–14) | 3 (1–8) | 3 (1–8) | 2 (1–6) | 3 (1–14) |
Anti‐CD20 antibody, n (%) | 41 (100) | 17 (100) | 16 (94·1) | 37 (94·9) | 111 (97·4) |
Any alkylating agent, n (%) | 39 (95·1) | 12 (70·6) | 14 (82·4) | 37 (94·9) | 102 (89·5) |
Bendamustine | 21 (51·2) | 4 (23·5) | 10 (58·8) | 17 (43·6) | 52 (45·6) |
Any purine analogue, n (%) | 2 (4·9) | 4 (23·5) | 6 (35·3) | 4 (10·3) | 16 (14) |
Fludarabine | 2 (4·9) | 3 (17·6) | 6 (35·3) | 3 (7·7) | 14 (12·3) |
Anthracyclines, n (%) | 21 (51·2) | 1 (5·9) | 3 (17·6) | 30 (76·9) | 55 (48·2) |
FL, Follicular lymphoma; LPL/WM, Lymphoplasmacytoid lymphoma/Waldenström macroglobulinaemia; MCL, Mantle cell lymphoma; MZL, Marginal zone lymphoma.